Cardiology Pharmacy Specialty Review Course - includes Workbook (No Recert Credit (Cert # L209247)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 05/27/2020
Content Release Date: 06/24/2020
Expiration Date: 06/01/2021
Activity Type: Application-based
CE Credits: 25.25 (ACPE only)
Activity Fee: $425 (ASHP member); $625 (non-member)

Accreditation for Pharmacists

The American College of Clinical Pharmacy and American Society of Health-System Pharmacists are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

Target Audience

These activities are intended for pharmacists who are seeking to update their knowledge and skills commensurate with a board certification examination in the areas listed below.

Activity Overview

This online course provides a robust preparatory curriculum for the pharmacy professional preparing for the Board of Pharmacy Specialties (BPS) Cardiology Specialty Certification Examination. Designed based on the domains, tasks, and knowledge statements developed by the BPS for the certification examination, this course will help you prepare for the exam by identifying areas needed for in‐depth review of cardiology issues by:

  • Reviewing pertinent clinical topics and practice skills
  • Providing exam practice questions
  • Listing valuable references for further study

This course is NOT intended for those obtaining recertification credit. To earn recertification credit, please see courses here:

These activities are part of the ACCP and ASHP professional development program.

Review Course

This course consists of 17 activities (see table below) and provides up to 25.25 hours of continuing pharmacy education credit. The Review Course includes case-based presentations for application to real-life scenarios, a practice exam along with correct answers, and links to the reference sources, and domains, tasks, and knowledge statements. To help you further prepare, this package includes a compilation of practice questions in the same format and rigor to help you prepare for the BPS Specialty Examination.       

Learning Activity

ACPE Number



ACPE Expiration Date

Primary Prevention of Cardiovascular Disease
and Public Health







Blood Pressure Management of Adult Patients 



Stable Atherosclerotic Disease 









Drug-Induced Cardiovascular Disease and Drugs to Avoid in Cardiovascular Disease



Chronic Heart Failure 



Acute Decompensated Heart Failure 



Cardiac Transplantation and Mechanical Circulatory Support 



Acute Coronary Syndromes 



Cardiovascular Emergencies 



Pulmonary Arterial Hypertension 



Specialized Topics in Cardiovascular Disease 



Pharmacogenomics of Cardiovascular Pharmacotherapies



Principles of Information Management and Education: Research Design, Biostatistics,  Literature, and Education and Training




Principles of Cardiology Pharmacy Practice Administration: Quality Improvement, Pharmacoeconomics, and Safe Medication Use 



























Learning Objectives

After participating in this CPE activity, learners should be able to: 

ACPE Number: 0217-9999-20-099-H01-P

  • Identify the pharmacotherapeutic agents that reduce the risk of developing cardiovascular disease (CVD).
  • Given a patient scenario, develop a treatment plan that incorporates lifestyle modifications and evidence-based pharmacotherapy to reduce the risk of an index cardiac event.
  • Develop a tobacco cessation plan for a patient who requests assistance for a quit attempt.
  •  Describe the role of selecting appropriate statin potency for the primary prevention of CVD.
  • Formulate discussion points that should be incorporated into a patient discussion regarding aspirin use for the primary prevention of CVD.
  • Advise a patient on the most appropriate nonpharmacologic and pharmacotherapeutic options for managing obesity.

ACPE Number: 0217-9999-20-100-H01-P

  • Describe the role of cholesterol and lipoproteins in the development of atherosclerotic cardiovascular disease (ASCVD).
  • Evaluate a patient’s ASCVD risk by appropriately using the 10-year ASCVD Risk Pooled Cohort Equations and optional risk markers.
  • Establish goals of therapy, statin intensity and create a monitoring plan for patients receiving lipid-lowering therapies.Establish goals of therapy, select an appropriate statin intensity, and create a monitoring plan for patients receiving lipid-lowering therapies for primary and secondary prevention of ASCVD.          
  • Develop an appropriate treatment regimen for patients who are statin intolerant or
  • unable to achieve goals of therapy on maximally tolerated statin therapy, according to the 2018 Guideline on the Management of Blood Cholesterol.
  • Identify appropriate indications for the use of triglyceride-lowering therapies to manage hypertriglyceridemia.
  • Evaluate the needs of special populations (e.g., those with diabetes, older adults, those with kidney disease), and adapt treatment strategies to optimize outcomes.
Blood Pressure Management in Adult Patients

ACPE Number: 0217-9999-20-102-H01-P

  • Develop an optimal pharmacologic treatment plan for a patient with hypertension (HTN) according to practice guidelines and clinical trial evidence.
  • Demonstrate appropriate drug selection and blood pressure goals for the treatment of HTN according to concomitant conditions and compelling indications.
  • Devise an evidence-based treatment strategy for resistant HTN to achieve blood pressure goals.
  • Construct appropriate drug therapy plans for the treatment of hypotension.
Stable Atherosclerotic Disease

ACPE Number: 0217-9999-20-103-H01-P

  • Recommend patient-specific pharmacologic therapy for the management of stable ischemic heart disease (SIHD).
  • Differentiate between the antianginal options for a patient with refractory angina.
  • Develop an optimal pharmacologic regimen and monitoring plan for patients with peripheral arterial disease (PAD) considering individual patient symptomatology and characteristics.
  • Develop an evidence-based pharmacologic regimen for secondary prevention of ischemic stroke and transient ischemic attack (TIA).
  • Recommend risk factor modification strategies to prevent a recurrent event for patients with SIHD, PAD, and ischemic stroke/TIA.

ACPE Number: 0217-9999-20-104-H01-P

  • Recommend a patient-specific pharmacotherapy plan to reduce the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF).
  • Devise an evidence-based pharmacotherapy plan for preventing and treating venous thromboembolism (VTE).
  • Analyze the need for anticoagulant therapy in patients with atrial fibrillation or VTE.
  • Determine appropriate reversal strategies for patients at risk of active bleeding, or actively bleeding while receiving anticoagulation therapy.
  • Determine appropriate selection and dosing of anticoagulant therapy on the basis of patient-specific factors and drug interactions.
  • Evaluate literature and clinical implications of data for patients receiving anticoagulant agents.

ACPE Number: 0217-9999-20-105-H01-P

  • Describe the principles of basic electrocardiogram (ECG) interpretation.
  • Compare and contrast risk factors for and etiologies, clinical features, signs and symptoms, and goals of therapy of sinus bradycardia, atrial fibrillation (AF), supraventricular tachycardia (SVT) (including Wolff-Parkinson-White [WPW] syndrome), premature ventricular complexes (PVCs), and ventricular tachycardia (VT).
  • Compare and contrast appropriate pharmacologic and nonpharmacologic treatment options for sinus bradycardia, AF, SVT, PVCs, and VT.
  • Compare and contrast the mechanisms of action of drugs used for ventricular rate control and conversion to and maintenance of sinus rhythm in patients with AF.
  • Describe the risk of thromboembolism in patients with AF and the importance of anticoagulation in this population.
  • Compare and contrast nonpharmacologic and pharmacologic methods of terminating and preventing recurrence of SVT
  • Compare and contrast nonpharmacologic and pharmacologic methods of terminating VT, preventing recurrence, and reducing the risk of sudden cardiac death
  • Develop evidence-based patient-specific pharmacotherapy plans for patients with symptomatic sinus bradycardia, AF, SVT (including WPW), PVCs, and VT.
  • Describe common and important drug-drug interactions associated with drugs used for the management of arrhythmias and their complications.
Drug Induced Cardiovascular Disease and Drugs to Avoid in Cardiovascular Disease

ACPE Number: 0217-9999-20-106-H01-P

  • Identify potential drug-induced cardiovasculardiseases.
  • Analyze a medication list to determine causative agents for common drug-induced cardiovascular diseases.
  • Evaluate potential medications that can contribute to the development of torsades de pointes.
  • Review anticancer therapies that cause cardiovascular toxicities.
  • Evaluate patient characteristics and laboratory values to assess the risk of heparin- induced thrombocytopenia and develop an appropriate treatment plan.
Chronic Heart Failure

ACPE Number: 0217-9999-20-107-H01-P

  • Given a patient with heart failure (HF), describe the classifications, staging, clinical presentation, etiologies, and diagnostic considerations.
  • Describe the pathophysiology of HF, focusing on the role that neurohormonal and other vasoactive agents play in HF progression.
  • Given a patient with chronic HF, devise an appropriate pharmacologic and nonpharmacologic therapeutic plan, with an emphasis on guideline-directed therapy and management.
  • Given a patient with chronic HF and several comorbidities, devise an appropriate evidence-based pharmacotherapy plan addressing specific comorbidities related to HF.
Acute Decompensated Heart Failure

ACPE Number: 0217-9999-20-108-H01-P

  • Classify a patient with acute decompensated heart failure (ADHF) into a hemodynamic subset based on signs/symptoms, laboratory values, and hemodynamic measures obtained via pulmonary artery catheter (PAC) monitoring.
  • Design an initial pharmacotherapeutic treatment and monitoring plan for a patient with ADHF based on hemodynamic subset.
  • Devise a modified treatment and monitoring plan in a patient with ADHF and diuretic resistance.
  • Compare and contrast the use of intravenous (IV) vasodilators and positive inotropes in the treatment of ADHF, and among the agents within each drug class.
  • List strategies for reducing the risk of heart failure (HF) readmission among patients recovering from ADHF.
Cardiac Transplantation and Mechanical Circulatory Support

ACPE Number: 0217-9999-20-109-H01-P

  • Evaluate levels of risk in the cardiac transplant candidate.
  • Derive rational peri- and postoperative rejection mitigation strategies in cardiac transplant recipients.
  • Devise effective thromboprophylactic strategies for patients receiving percutaneous ventricular assist device support.
  • Construct safe and effective drug therapy regimens for patients receiving extracorporeal membrane oxygenation support 
  • Design effective treatment plans for patients with complications of durable left ventricular assist device therapy.
Acute Coronary Syndromes

ACPE Number: 0217-9999-20-110-H01-P

  • Distinguish between reperfusion strategies for acute coronary syndrome (ACS): ST- segment elevation myocardial infarction (STEMI) and non–ST-segment elevation (NSTE) ACS.
  • Devise a pharmacotherapeutic treatment plan for a patient with STEMI undergoing primary percutaneous coronary intervention (PCI) and for a patient with NSTE-ACS undergoing an early invasive or ischemic-guided approach.
  • Differentiate between the best possible pharmacologic options for preventing thrombotic events in the acute management of ACS.
  • Analyze differences in evidence, pharmacology, pharmacokinetics, drug-drug interactions, monitoring, and adverse events between the P2Y12 inhibitors and anticoagulants used in ACS management.
  • Devise an individualized evidence-based treatment plan for patients in need of secondary prevention post-ACS, including mortality-reducing therapies.
Cardiovascular Emergencies

ACPE Number: 0217-9999-20-111-H01-P

  • Choose appropriate management pathways/treatment for a patient with cardiac arrest according to patient presentation.
  • Differentiate between the various categories of shock.
  • Select the optimal management strategies for the various types of shock.
  •  Construct a pharmacotherapy regimen for the various hypertensive crises.
  •  Select an appropriate management plan for a patient presenting with acute aortic syndrome.
  •  Design a pharmacotherapy plan for the management of acute ischemic stroke.
Pulmonary Arterial Hypertension

ACPE Number: 0217-9999-20-112-H01-P

  • Describe the classification of pulmonary hypertension and implications for treatment.
  • Discuss the importance of pulmonary arterial hypertension (PAH) pathobiology and the role of various pathways as treatment targets in the development of PAH-specific treatment.
  • Define treatment goals for the management of PAH.
  • Outline targeted medications for PAH, including indications, dosing, monitoring, and their place within current treatment algorithms.
  • Identify common adverse effects and drug interactions associated with PAH medications.
  • Highlight appropriate treatment approaches for the management of decompensated PAH.
  • Design a treatment plan for a patient with PAH.
Specialized Topics in Cardiovascular Disease

ACPE Number: 0217-9999-20-113-H01-P

  • Recommend empiric antibiotic therapy for patients with suspected infective endocarditis (IE).
  • Develop a therapeutic plan regarding medication therapy for patients with IE or patients requiring prophylactic therapy for IE prevention.
  • Identify patients who require IE prophylactic therapy.
  • Develop a treatment plan for patients with pericarditis.
  • Recommend appropriate therapy for patients with myocarditis.
  • Plan a medication therapy regimen for patients with valvular heart disease.
Pharmacogenomics of Cardiovascular Disease

ACPE Number: 0217-9999-20-114-H01-P

  • Apply Clinical Pharmacogenetics Implementation Consortium (CPIC) guidance in the clinical setting.
  • Associate clinically actionable genetic polymorphisms with response to cardiovascular pharmacotherapies.
  • For a given patient, estimate therapeutic response to antiplatelet therapy using
  • CYP2C19 genotype information.
  • For a given patient, analyze the impact of the SLCO1B1 genotype on the risk of myopathy with statins.
  • For a given patient, estimate the dose of warfarin using VKORC1 and CYP2C9 genotype information.
Principles of Information Management and Education Research Design, Biostatistics, and Literature Training and Education and Training

ACPE Number: 0217-9999-20-115-H04-P

  • Identify different types of data (nominal, ordinal, continuous) to determine the appropriate type of statistical test (parametric vs. nonparametric).
  • Select appropriate statistical tests based on the sample distribution, data type, and study design.
  • Identify the most appropriate study design to answer a given clinical question.
  • Describe the key tenets of internal and external validity of cardiovascular-related trials.
  • Describe the advantages and disadvantages of surrogate and composite outcomes in cardiovascular studies.
Principles of Cardiology Pharmacy Practice Administration: Protocol Development and Quality Improvement, Pharmacoeconomics and Safe Medication Use

ACPE Number: 0217-9999-20-116-H04-P

  • Develop policies, procedures, and clinical protocols related to the medication use process.
  • Identify formulary management activities to improve the prescribing of safe, effective, and affordable treatments in an organization.
  • List high-risk medications and medication-related processes that are suited for a medication use evaluation (MUE) and be capable of managing the MUE process.
  •  Identify sources of quality measures relevant to your organization, and use quality and process improvement methods to achieve optimal outcomes.
  • Describe proper documentation practices for clinical pharmacy services and identify the need for accurate documentation.
  • Review pharmacoeconomic principles and their application to patient care.
  • Define a pharmacist’s scope of practice and the importance of credentialing and privileging.
  • Compare a medication error, adverse drug event (ADE), adverse drug reaction (ADR), and preventable ADE.
  • Design an ADE reporting program, including committee structure, committee reporting mechanisms, and methods of detecting, reporting, and managing ADEs.

Planners, Presenters, and Reviewers

William L. Baker, Pharm.D., FCCP, FACC, FAHA
Associate Professor, Department of Pharmacy Practice
University of Connecticut School of Pharmacy
Storrs, Connecticut
Scott Bolesta, Pharm.D., FCCP, FCCM, BCPS
Associate Professor, Department of Pharmacy Practice
Nesbit School of Pharmacy, Wilkes University
Wilkes-Barre, Pennsylvania
James C. Coons, Pharm.D., FCCP, BCCP
Associate Professor, University of Pittsburgh School of Pharmacy
Clinical Pharmacist, Cardiology, UPMC Presbyterian Hospital
PGY2 Cardiology Residency Program Director
Pittsburgh, Pennsylvania
Rhonda Cooper-DeHoff, Pharm.D., M.S., FCCP, FAHA, FACC
Associate Professor and University Term Professor
Department of Pharmacotherapy and Translation Research and Division of Cardiovascular Medicine
Colleges of Pharmacy and Medicine
Associate Director, Center for Pharmacogenomics
University of Florida
Gainesville, Florida
Paul P. Dobesh, Pharm.D., FCCP, BCPS, BCCP
Professor of Pharmacy Practice
University of Nebraska Medical Center College of Pharmacy
Omaha, Nebraska
Steve Dunn, Pharm.D., FCCP, FAHA, BCPS, BCCP
Pharmacy Clinical Coordinator, Heart and Vascular
University of Virginia Health System
Charlottesville, Virginia
Shannon Finks, Pharm.D., FCCP, FACC, BCPS, BCCP, AHSCP-CHC
Professor, Department of Clinical Pharmacy
University of Tennessee College of Pharmacy
Memphis, Tennessee
Doug Jennings, Pharm.D., FCCP, FAHA, FACC, FHFSA, BCPS
Clinical Pharmacy Manager, Heart Transplant
New York Presbyterian Hospital
Columbia University Irving Medical Center
New York, New York
Tracy E. Macaulay, Pharm.D., BCPS-AQ Cardiology, BCCP, AACC
Associate Professor
University of Kentucky College of Pharmacy
Cardiology Clinical Pharmacy Specialist
UK HealthCare
Lexington, Kentucky
Zachary Noel, Pharm.D., BCPS, BCCP
Assistant Professor, Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Global Medical Information Specialist
Med Communications, Inc.
Memphis, Tennessee
Robert Page II, Pharm.D., MSPH, FCCP, FASHP, FAHA, FHFSA, BCPS-AQ Cardiology, BCGP
Professor, Department of Clinical Pharmacy
Professor, Department of Physical Medicine/Rehabilitation
University of Colorado Skaggs
School of Pharmacy and Pharmaceutical Sciences
Aurora, Colorado
Mary Parker, Pharm.D., FCCP, FASHP, BCPS, BCCP
Clinical Pharmacy Specialist-Ambulatory Care
Durham VA Medical Center
Durham, North Carolina
Brent Reed, Pharm.D., BCPS, BCCP
Associate Professor of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Baltimore, Maryland
Kelly C. Rogers, Pharm.D., FCCP, FACC, BCCP
Professor, Department of Clinical Pharmacy and
Translational Science
University of Tennessee College of Pharmacy
Memphis, Tennessee
Dustin Spencer, Pharm.D., MBA, BCPS, BCCP
Clinical Director, Cardiopulmonary Diseases
Cardinal Health
Houston, Texas

Theodore Berei, Pharm.D., MBA, BCPS, BCCP
Clinical Specialist Advanced Heart Failure University of Wisconsin Health
Madison, Wisconsin
Brandon Cave, Pharm.D., BCCP, ASH-CHC
Clinical Pharmacy Specialist - Cardiology
Methodist University Hospital
Memphis, Tennessee
Megan Clarke, Pharm.D., BCPS, BCCP
Cardiology/Anticoagulation Clinical Specialist
University of Michigan
Jackoline Costantino, Pharm.D., BCCP
Cardiology and Transplant Clinical Pharmacy Specialist, UK Health Care
Lexington, Kentucky
Mary Blanton Covell, Pharm.D., MPH, BCPS, BCCP
Pharmacy Clinical Coordinator
Ephraim McDowell Regional Medical Center
Danville, Kentucky
Anne Denham, Pharm.D., BCPS-AQ Cardiology
Clinical Pharmacy Specialist
Kaiser Permanente Colorado
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, Colorado
Dave L. Dixon, Pharm.D.
Vice Chair for Clinical Services Associate Professor in Ambulatory Care
Virginia Commonwealth University School of Pharmacy
Richmond, Virginia
Augustus Hough, Pharm.D., BCCP, BCPS-AQ Cardiology
Clinical Pharmacy Specialist - Cardiology; Director, PGY2 Cardiology Pharmacy Practice Residency
West Palm Beach VA Medical Center
West Palm Beach, Florida
Cynthia Jackevicius, Pharm.D., M.Sc., FCCP, FAHA, FCCS, BCCP, BCPS-AQ Cardiology
Western University of Health Sciences; Senior Adjunct Scientist
Institute for Clinical Evaluative Sciences
Los Angeles, California
Yee Ming Lee, Pharm.D., BCPS
Assistant Professor, Department of Clinical Pharmacy
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, Colorado
Associate Professor, Department of Clinical Pharmacy
University of Colorado Anschutz Medical Campus
Aurora, Colorado
Kristin Montarella, Pharm.D., BCPS, BCPP
Associate Professor
Southwest Oklahoma State University
Weatherford, Oklahoma
Kari L. Olson, Pharm.D., FCCP, BCPS
Clinical Pharmacy Specialist Outcomes Research
Kaiser Permanente
National Pharmacy; Associate Clinical Professor
University of Colorado Skaggs
School of Pharmacy
Aurora, Colorado
Jerrica E. Shuster, PharmD, BCPS, BCCP
Clinical Pharmacist, Heart Failure/Transplant
Barnes Jewish Hospital
Andrew J. Smith, Pharm.D., FCCP, BCCP, BCPS
Clinical Associate Professor-UMKC
School of Pharmacy
Kansas City, Missouri
Barbara S. Wiggins, Pharm.D., FCCP, FAHA, FNLA, FACC, BCPS, BCCP, BCCCP, CLS
Clinical Pharmacy Specialist - Cardiology
Medical University of South Carolina
Adjunct Professor
Medical University of South Carolina
School of Pharmacy
Charleston, South Carolina
Kevin Wohlfarth, Pharm.D., BCPS, BCCCP, BCCP
Clinical Pharmacist - Cardiology
ProMedica Toledo Hospital
Toledo, Ohio

Erik E. Abel, Pharm.D., BCPS
Seth R. Bauer, Pharm.D., FCCP, FCCM
Scott T. Benken, Pharm.D.,
Bradley A. Boucher, Pharm.D., FCCP, FNAP, MCCM, BCPS
Gretchen M. Brophy, Pharm.D., FCCP, BCPS
Aaron M. Cook, Pharm.D.,
James C. Coons, Pharm.D., FCCP, BCPS-AQ Cardiology
Mitchell J. Daley, Pharm.D., BCPS
Dave L. Dixon, Pharm.D.
Christopher R. Ensor, Pharm.D, BCPS-AQ Cardiology, FAST, FCCP
Shannon Finks, Pharm.D., FCCP, BCPS-AQ Cardiology, ASH-CHC
Curtis Haas, Pharm.D., FCCP, BCPS
Karen McConnell, Pharm.D., FCCP, BCPS-AQ Cardiology, ASH-CHC
Katherine O’Neal, Pharm.D., MBA, BCACP
Evan Sisson, Pharm.D., MSHA, CDE
Kevin M. Sowinski, Pharm.D., FCCP
James E. Tisdale, Pharm.D., FCCP, FAPhA, FNAP
Teresa Truong, Pharm.D., BCPS, CDE
Timothy E. Welty, Pharm.D., FCCP, BCPS


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP and ACCP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP and ACCP education activities are qualified and selected by ASHP and ACCP and required to disclose any relevant financial relationships with commercial interests. ASHP and ACCP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Clinical Investigator: James C. Coons (United Therapeutics)
  • Received Grant Funding/Research Support: James C. Coons (United Therapeutics), William L. Baker (Portola)
  • Consultant/Member of Advisory Board: Paul P. Dobesh (Boehringer Ingelheim, Pfizer/BMS Alliance, Janssen Pharmaceuticals, Portola Pharmaceuticals), William L. Baker (Portola, Bayer), Steven P. Dunn (Abiomed, Inc.), Douglas L. Jennings (Abiomed, Inc., Janssen, Novartis)
  • Speaker’s Bureau: Anastasia L. Armbruster (AstraZeneca), Brandon E. Cave (Portola), Jerrica E. Shuster (Janssen)
  • Other: Yee Ming Lee (Topic Editor Pharmacogenomics, Dynamed Plus), Brett A. Vickey (Stockholder Amarin and Novartis)

All other planners, presenters, reviewers, ASHP and ACCP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Methods and CE Requirements

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

System Technical Requirements

Learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. 

View the minimum technical and system requirements for learning activities. 


These activities were developed by ACCP and ASHP.

To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for Board Certification Examinations.